Phase 3Not yet recruiting

A study to compare heart failure medicines in one combined pill with usual care. (S005207-229)

A multinational, multicenter, prospective, randomized, open-label, event-driven trial with two parallel arms, to compare the efficacy and safety of Guideline-Directed Medical Therapy (GDMT) with the use of Fixed-Dose Combination (FDC) strategy versus usual care for the management of Heart Failure.

Sponsor
Institut De Recherches Internationales Servier IRIS (Industry)
Enrollment
275 planned
Conditions
Heart Failure; Heart failure
Interventions
Hard-gelatin capsules containing 10/10/50 mg of Dapagliflozin/Bisoprolol fumarate/Eplerenone; Hard-gelatin capsules containing 10/50 mg of Dapagliflozin/Eplerenone; Hard-gelatin capsules containing 10/2.5 mg of Dapagliflozin/Bisoprolol fumarate; Hard-gelatin capsules containing 10/25 mg of Dapagliflozin/Eplerenone; Hard-gelatin capsules containing 10/5 mg of Dapagliflozin/Bisoprolol fumarate; Hard-gelatin capsules containing 10/10/25 mg of Dapagliflozin/Bisoprolol fumarate/Eplerenone; Hard-gelatin capsules containing 10/5/50 mg of Dapagliflozin/Bisoprolol fumarate/Eplerenone; Hard-gelatin capsules containing 10/5/25 mg of Dapagliflozin/Bisoprolol fumarate/Eplerenone; Hard-gelatin capsules containing 10/10 mg of Dapagliflozin/Bisoprolol fumarate
Ages
adults, older adults
Registry
CTIS2026-526510-90-00

Full record on the EU Clinical Trials Information System

From the registry

Main objective: To evaluate in participants admitted for acute HF the effect of treatment delivered as FDC (Fixed-dose combination) based strategy compared to usual care on HFE (Heart Failure Event) and cardiovascular death

Primary outcomes

  • Times to occurrences of total (first and recurrent) HFEs and cardiovascular death

History

  1. Enrollment up to 275

    , from 205 to 275

  2. Last registry update

  3. Enrollment up to 205

    , from 90 to 205

  4. Registered